Dynamic neural states underpin motor symptom severity in Parkinson's disease: a longitudinal analysis of chronic cortico-subthalamic nucleus recordings.
Where this comes from
- Record sourced from PubMed, PMID 42119302.
- Also identified by DOI 10.1016/j.ebiom.2026.106293.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Motor symptoms in Parkinson's disease (PD) may arise due to transient, network-wide neural dynamics that extend beyond beta-band oscillatory activity within the motor cortical-subthalamic nucleus (STN) circuit. We applied a four-state Hidden Markov Model (HMM) to identify states of local and interregional oscillatory synchrony from chronic motor cortical and STN recordings (1046 h from 10 hemispheres) in five patients with PD (mean age 49 years), with concurrent measurements of bradykinesia, dyskinesia and tremor quantified using wearable sensors. Neural states exhibited distinct spectral and temporal features relating to symptom severity. Two states exhibited spectral signatures-particularly STN low and high gamma, STN delta/alpha, cortical beta, and cortico-STN beta coherence-that predicted worsening bradykinesia. STN beta oscillations were not consistent predictors of bradykinesia (p = 0.52), but did predict worsening tremor (p < 0.01) and also improvements in dyskinesia severity (p < 0.001), in a state specific manner. These states also displayed compensatory features associated with bradykinesia amelioration, including cortical delta/alpha activity, cortical high gamma, and cortico-STN high gamma coherence. Additionally, we identified a state, marked by STN beta without cortico-STN beta coherence, whose increased lifetimes and occurrence improved motor function (p < 0.001). Our findings highlight the multidimensional nature of motor impairments in PD and suggest that adaptive interventions targeting state features-rather than single frequency bands-may offer new opportunities for personalised neuromodulation. AO: MRC Clinician Scientist Fellowship (MR/W024810/1), Rosetrees Trust/Race Against Dementia Team award, Oxford Hospitals Charity, and the Jon Moulton Charity Trust. TL: China Scholarship Council.